Phase 0 Workshop at the 20th EORTC-NCI-AACR Symposium, Geneva.
作者信息
Camporesi S
机构信息
European School of Molecular Medicine, IFOM-IEO Campus, Via Adamello, 16, 20139 Milan, Italy.
出版信息
Ecancermedicalscience. 2008;2:107. doi: 10.3332/ecancer.2008.107. Epub 2008 Nov 12.
Abstract
摘要
相似文献
1
Phase 0 Workshop at the 20th EORTC-NCI-AACR Symposium, Geneva.第20届欧洲癌症研究与治疗组织-美国国立癌症研究所-美国癌症研究协会研讨会（日内瓦）0期研讨会
Ecancermedicalscience. 2008;2:107. doi: 10.3332/ecancer.2008.107. Epub 2008 Nov 12.
2
EORTC-NCI-AACR--16th Symposium. Highlights. 28 September-1 October 2004, Geneva, Switzerland.
IDrugs. 2004 Nov;7(11):968-70.
3
4
EORTC-NCI-AACR--16th Symposium. Kinase inhibitors. 28 September-1 October 2004, Geneva, Switzerland.
IDrugs. 2004 Nov;7(11):965-7.
5
EORTC-NCI-AACR--20th symposium molecular targets and cancer therapeutics.欧洲癌症研究与治疗组织-美国国立癌症研究所-美国癌症研究协会第20届分子靶点与癌症治疗研讨会
IDrugs. 2008 Dec;11(12):855-6.
6
7
14th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Frankfurt, Germany.第14届欧洲肿瘤研究与治疗组织-美国国立癌症研究所-美国癌症研究协会分子靶点与癌症治疗研讨会，德国法兰克福
Clin Lung Cancer. 2003 May;4(6):333-5. doi: 10.1016/s1525-7304(11)70301-1.
8
EORTC-NCI-AACR - 18th Symposium - Molecular Targets and Cancer Therapeutics. Updates on cancer drugs.
IDrugs. 2007 Jan;10(1):3-4.
9
AACR-NCI-EORTC--17th Symposium: Molecular Targets and Cancer Therapeutics.
IDrugs. 2006 Feb;9(2):90-2.
10
11th NCI-EORTC-AACR symposium on new drugs in cancer therapy. November 7-10, 2000. Abstracts.
Clin Cancer Res. 2000 Nov;6(11 Suppl):4467s-4597s.
本文引用的文献
1
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.聚（ADP - 核糖）聚合酶抑制剂ABT - 888用于晚期恶性肿瘤患者的0期临床试验。
J Clin Oncol. 2009 Jun 1;27(16):2705-11. doi: 10.1200/JCO.2008.19.7681. Epub 2009 Apr 13.
2
Designing phase 0 cancer clinical trials.设计0期癌症临床试验。
Clin Cancer Res. 2008 Jun 15;14(12):3675-82. doi: 10.1158/1078-0432.CCR-07-4560.
3
The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.I期癌症试验方法的发展：药代动力学和药效学终点的应用为0期癌症临床试验奠定了基础。
Clin Cancer Res. 2008 Jun 15;14(12):3664-9. doi: 10.1158/1078-0432.CCR-07-4559.
4
Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient.纳入临床药效学的肿瘤0期试验：从概念到患者。
Clin Cancer Res. 2008 Jun 15;14(12):3658-63. doi: 10.1158/1078-0432.CCR-07-4562.
5
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.癌症药物研发中的0期临床试验：从美国食品药品监督管理局指南到临床实践
Mol Interv. 2007 Dec;7(6):325-34. doi: 10.1124/mi.7.6.9.
6
The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials.美国食品药品监督管理局（FDA）和欧洲药品管理局（EMEA）指南对与0期试验相关的药物研发的影响。
Br J Cancer. 2007 Sep 3;97(5):577-81. doi: 10.1038/sj.bjc.6603925. Epub 2007 Aug 28.
7
Capecitabine.卡培他滨
Oncologist. 2007 Feb;12(2):152-5. doi: 10.1634/theoncologist.12-2-152.
8
Compressing drug development timelines in oncology using phase '0' trials.利用“0期”试验缩短肿瘤学药物研发周期。
Nat Rev Cancer. 2007 Feb;7(2):131-9. doi: 10.1038/nrc2066.
9
The phase 0 microdosing concept.0期微剂量给药概念。
Br J Clin Pharmacol. 2006 Apr;61(4):367-70. doi: 10.1111/j.1365-2125.2006.02575.x.
10
Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development?
J Clin Oncol. 2005 Aug 20;23(24):5417-9. doi: 10.1200/JCO.2005.05.907. Epub 2005 Jul 18.
Zotero 插件